This case report represents a patient with metastatic melanoma of unknown primary with durable response
by conventional chemotherapy and palliative radiation.
In sum, single agent durable responses
of CTLA-4 inhibitors, PD-1 antagonists, and ORR in almost 25% of patients provide a strong rationale for checkpoint inhibitors being used as backbone in combination immunotherapy regimens.
*95% of patients receiving a durable response
were alive at six months.
The goal of the present research was to determine which additional manipulations might be added to a traditional DRO schedule to produce durable response
elimination in the laboratory.
It was determined to proceed with aggressive measures, given the potential for long-term durable responses
from immune checkpoint inhibitor therapy.
During the phase three study, which was the basis for the Committee for Medicinal Products for Human Use opinion, Imlygic was claimed to significantly extend the primary endpoint of durable response
rates compared with granulocyte-macrophage colony-stimulating factor.
In a retrospective series of 184 patients who received HDCT, 63% achieved a durable response
with high-dose CE, either with or without a preceding cycle of VeIP.
At 1 year, 17 (71%) of the 24 patients remained in remission, indicating that rituximab could provide durable response
and permit the discontinuation of chemotherapy in most patients.
Interferon alfa may be the treatment of choice for a young, highly motivated patient willing to withstand its significant side effects in order to undergo a relatively short course of therapy with a more durable response
and a higher rate of hepatitis B surface antigen loss compared with oral adefovir or entecavir therapy.
Herz and associates theorize that idiopathic childhood urethritis is a manifestation of poor relaxation of the pelvic floor, and treating the underlying dysfunctional elimination can lead to a quicker and more durable response
The humanized antibody, epratuzumab, is being studied in a pivotal clinical trial to treat indolent non-Hodgkin's lymphoma patients who either do not respond, or who do not have a durable response
, to the currently available antibody therapy, Rituxan (Rituximab, IDEC/Genentech).
ARCHWAY Study: Results from this open-label Phase 2 clinical trial evaluating the safety and activity of SAGE-217 in 35 adult men and women with moderate to severe bipolar I/II disorder with a major depressive episode demonstrated a rapid and durable response
to treatment as measured by the Montgomery-Asberg Depression Rating Scale (MADRS) and a statistically significant improvement compared to baseline at Day 15; the effect was maintained through the end of the follow-up period at Day 42.